The liver and statin drug therapy: Uncertain navigation in the sea of risk-benefit

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 4, 2003, Pages 303-306

  Caldwell, Stephen H ^a   Zaidman, Jeffrey S ^a   Hespenheide, Elizabeth E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; TROGLITAZONE;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FATTY LIVER; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER BIOPSY; LIVER DISEASE; LIVER FAILURE; LIVER MITOCHONDRION; LIVER TOXICITY; MUSCLE DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TOXIC HEPATITIS;

HEPATITIS, TOXIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; RISK ASSESSMENT; UNITED STATES;

EID: 0038795468     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.833     Document Type: Editorial

References (43)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-2497.
2. Eidelman RS, Lamas GA, Hennekens CH. The new national cholesterol education program guidelines. Arch Intern Med 2002;162:2033-2036.
3. Stein EA. Adult Treatment Panel III and the Management of Dyslipidemia Risk Factors. Postgraduate Medicine Special Report. McGraw Hill Publishers: Minneapolis, MN, 2002; 12-17.
4. Ballantyne CM. Hyperlipoproteinemias. In Conn's Current Therapy, Rakel RE, Bope ET (eds). WB Saunders: Philadelphia, 2002.
5. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
6. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
7. Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ. Suppression of apolipoprotein B production during treatment of cholesterol ester storage disease with lovastatin: implications for regulation of apoprotein B synthesis. J Clin Invest 1987; 80: 1692-1697.
8. Watts GF, Naoumova RP, Kelly JM. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997; 273: E462-E470.
9. Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002; 97: 115-121.
10. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42: 333-337.
11. Nakahara K, Kuriyama M, Sonoda Y, et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological electrophysiological and biochemical study. Toxicol Appl Pharmacol 1998; 152: 99-106.
12. Sinzinger H, Lupattelli G, Chehne F. Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. Atherosclerosis 2000; 153: 255-256.
13. Physicians Desk Reference (57th edn). Medical Economics Company: Montrale, NJ, 2003.
14. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000; 85: 15E-19E.
15. Andrade SE, Donahue JG, Chan KA, Watson DJ, Platt R. Liver function testing in patients on HMG-CoA reductase inhibitors. Pharmacoepidemiol Drug Safe 2003; 12: 307-313.
16. Applegate WB. Elderly patients' adherence to statin therapy. JAMA 2002; 288: 495-497.
17. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929-1934.
18. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
19. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
20. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
21. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-692.
22. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and post-transplantation non-alcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
23. Contos MJ, Cales W, Sterling RK, et al. Development of non-alcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373.
24. Caldwell SH, Han K, Hess CE. Thrombocytopenia and unrecognized cirrhosis. Ann Int Med 1997; 127: 572-573.
25. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological and biochemical study. Int J Obes 1984; 8: 107-115.
26. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
27. Garcia-Monzon C, Martin-Perez E, Lo Iacono O, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-724.
28. Dixon JB, Bathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
29. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594-598.
30. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
31. Powell EE, Cooksley WG, Hanson R, Searll J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
32. Bacon BR, Farahvish MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
33. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
34. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-434.
35. Berson A, De Beco V, Letteron P, et al. Steatohepatitis inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764-774.
36. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-1664.
37. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898-904.
38. Horlander JC, Kwo PY, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH (abstract). Gastroenterology 2001; 120: A544.
39. Nair S, Wiseman M. HMG-CoA reductase inhibitors in no alcoholic fatty liver disease: is their potential hepatotoxicity an issue in these patients? A case control study based on histology. Hepatology 2002; 36: 409A.
40. Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001; 46: 376-378.
41. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-585.
42. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferases levels. Ann Intern Med 2002; 137: 1-9.
43. Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality and causes of death in type 2 diabetic patients. Diabetes Res Clin Pract 1989; 7: 33-40.